

Docket: 7210.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:

James L. Madara

Application No.:

10/762,388

Filing Date:

Title:

January 22, 2004

Modulation of Inflammation Related

to Columnar Epithelia

Examiner:

Unknown

Group Art Unit:

Unknown

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Barlax a avery (Signature)

Dear Sir:

Pursuant to 37 CFR § 1.97(b), the references listed on the attached Form PTO-1449 (4 sheets, submitted in duplicate) are brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. This IDS is being filed before the mailing of a first office action on the merits. In accordance with 37 CFR § 1.97(b), no statement or fee is required.

Copies of the references cited are not enclosed, as allowed under 37 CFR § 1.98(d). Each item on the enclosed Form PTO-1449 was cited to, or cited by, the Office in U.S. Patent No. 6,353,026, issued on March 5, 2002 to which priority is claimed under 35 U.S.C. § 120, in the present application.

Respectfully submitted,

DORSEY & WHITNEY LLP Customer Number 25763

Date: Dar

123, Var

By:

Scott D. Rothenberger, (Reg. No. 41,277)

Intellectual Property Department Suite 1500, 50 South Sixth Street Minneapolis, MN 55402-1498

(612) 340-8819

PTO/SB/08A (10/01) (modified) . U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Substitute for form 1449A/PTO **Application Number** 10/762.388 January 22, 2004 **Filing Date** INFORMATION DISC **First Named Inventor** James L. Madara STATEMENT BY APPLICANT Art Unit Unknown (use as many sheets as necessary) **Examiner Name** Unknown **Sheet** 1 of 4 **Attorney Docket Number** 7210.03 **U.S. PATENT DOCUMENTS** Pages, Columns, Lines, Where DOCUMENT NUMBER Cite **Publication Date** Name of Patentee or Relevant Passages or Initials No Number - Kind Code (if known) MM-DD-YYYY Applicant of Cited Document Relevant Figures Appear 5,441,951 8-1995 Serhan US-5,648,512 7-1997 Serhan US-6,353,026 3-2002 Serhan US-6,458,839 10-2002 Madara et al. US-6,699,905 3-2004 Madara et al. US-US-FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENT Number - Kind Code Pages, Columns, Lines, TRANSLATION Country **Publication Date** *Examine Cite Name of Patentee or Where Relevant Passages Code: (if known) Initial No. MM-DD-YYYY or Relevant Figures Appear Applicant of Cited Document YES NO **PCT** WO 94/29262 12-1994 П PCT WO 95/01179 1-1995 П PCT WO 00/54767 9-2000 П **OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS** Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the TRANSLATION *Examine Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials No. number(s), publisher, city and/or country where published YES NO Weissmann, G., Smolen, J. E., and Korchak, H. M. (1980) Release of inflammatory mediators П from stimulated neutrophils. N. Engl. J. Med. 303, 27-34 Serhan, C. N., Haeggstrom, J. Z., and Leslie, C. C. (1996) Lipid mediator networks in cell П signaling: update and impact of cytokines. FASEB J. 10, 1147-1158 Weiss, S. J. (1989) Tissue destruction by neutrophils. N. Engl. J. Med. 320, 365-376 П

11 6 4 1 1 T

Serhan, C. N. (1994) Lipoxin biosynthesis and its impact in inflammatory and vascular events.

Borgeat, P., and Naccache, P. H. (1990) Biosynthesis and biological activity of leukotriene B4.

Biochim. Biophys. Acta 1212, 1-25

Clin. Biochem. 23, 459-468

П

П

Substitut	e for	form 1449A	/PTO		Application Number	10/762,388						
INIE	∩E		אר ב	ISCLOSURE	Filing Date	January 22, 2004		-				
				APPLICANT	First Named Inventor	James L. Madara						
317		_		as necessary)	Art Unit	Unknown						
	(uc	ie as many	0,10010	as necessary)	Examiner Name	Unknown						
Sheet		2	of	4	Attorney Docket Number	7210.03						
	OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS											
		Yokomizo, T., Izumi, T., Chang, K., Takuwa, T., and Shimizu, T. (1997) A G-protein-coupled receptor for leukotriene B ₄ that mediates chemotaxis. <i>Nature</i> 387, 620-624										
				no, M., Reardon, E. M., IL-60 cells. <i>Blood</i> 81, 33	and Serhan, C. N. (1993) Ind 395-3403	uction of functional lipoxin						
			of a be		, Salvemini, D., Lee, L., ar in Prostaglandin, Thromboxan							
		Chiang, N., Takano, T., Clish, C. B., Petasis, N. A., Tai, HH., and Serhan, C. N. (1998) Aspirintriggered 15-epi-lipoxin A ₄ (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA ₄ ELISA. <i>J. Pharmacol Exper. Ther.</i> 287, 779-790										
		Serhan, C. N., Maddox, J. F., Petasis, N. A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H. R., Colgan, S. P., and Madara, J. L. (1995) Design of lipoxin A ₄ stable analogs that block transmigration and adhesion of human neutrophils. <i>Biochemistry</i> 34, 14609-14615										
		Takano, T., Fiore, S., Maddox, J. F., Brady, H. R., Petasis, N. A., and Serhan, C. N. (1997) Aspirin-triggered 15-epi-lipoxin A ₄ (LXA ₄) and LXA ₄ Stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. <i>J. Exp. Med.</i> 185, 1693-1704										
		Owman, C., Garzino-Demo, A., Cocchi, F., Popovic, M., Sabirsh, A., and Gallo, R. (1998) The leukotriene B ₄ receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. <i>Proc. Natl. Acad. Sci.</i> 95, 9530-9534										
		Marcus, A. J. (1995) Aspirin as prophylaxis against colorectal cancer. <i>N. Engl. J. Med.</i> 333, 656-658										
		Vainio, H., and Morgan, G. (1997) Aspirin for the second hundred years: new uses for an old drug. <i>Pharmacol Toxicol</i> 81, 151-152										
•		Herschman, H. R. (1998) Recent progress in the cellular and molecular biology of prostaglandin synthesis. <i>Trends in Cardiovasc. Med.</i> 8, 145-150										
		Takano, T., Clish, C. B., Gronert, K., Petasis, N., and Serhan, C. N. (1998) Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epilipoxin A ₄ and novel lipoxin B ₄ stable analogues. <i>J. Clin. Invest.</i> 101, 819-826										
		Billah, M. M., Eckel, S., Mullmann, T. J., Egan, R. W., and Siegel, M. I. (1989) Phosphatidylcholine hydrolysis by phospholipase D determines phosphatidate and diglyceride levels in chemotactic peptide-stimulated human neutrophils. Involvement of phsophatidate										
		phosphohydrolase in signal transduction. <i>J. Biol. Chem.</i> 264, 17069-17077 Wakelam, M. J. O., Martin, A., Hodgkin, M. N., Brown, F., Pettit, T. R., Cross, M. J., De Takats, P. G., and Reynolds, J. L. (1997) Role and regulation of phospholipase D activity in normal and cancer cells. <i>Advances in Enzyme Regulation</i> 37, 29-34										

1-

											
Substitute for form 1449A/PTO					Application Number	10/762,388					
INF	ΩF	≥ΝΛΔΤΙ <i>(</i>	JN D	ISCLOSURE	Filing Date	January 22, 2004					
				APPLICANT	First Named Inventor	James L. Madara					
0.,				as necessary)	Art Unit	Unknown					
	`				Examiner Name	Unknown					
Sheet		3	of	4	Attorney Docket Number	7210.03					
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS											
		Olson, S. C., and Lambeth, J. D. (1996) Biochemistry and cell biology of phospholipase D in human neutrophils. <i>Chem. Phys. Lipids</i> 80, 3-19									
			Steed, P. M., Clark, K. L., Boyar, W. C., and Lasala, D. J. (1998) Characterization of human PLD2 and the analysis of PLD isoform splice variants. <i>FASEB J.</i> 12, 1309-1317								
		Wakelam	Martin, A., Saqib, K. M., Hodgkin, M. N., Brown, F. D., Pettit, T. R., Armstrong, S., and Wakelam, M. J. O. (1997) Role and regulation of phospholipase D signalling. <i>Biochem. Soc. Trans.</i> 25, 1157-1160								
				asis, N. A., and Serhan, (e 389, 985-989	C. N. (1997) Polyisoprenyl ph	nosphates in intracellular					
		acid as a	Agwu, D. E., McPhail, L. C., Sozzani, S., Bass, D. A., and McCall, C. E. (1991) Phosphatidic acid as a second messenger in human polymorphonuclear leukocytes. Effects on activation of NADPH oxidase. <i>J. Clin. Invest.</i> 88, 531-539								
		Pettit, T. R., Martin, A., Horton, T., Liossis, C., Lord, J. M., and Wakelam, M. J. O. (1997) Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions. <i>J. Biol. Chem.</i> 272, 17354-17359									
			Gomez-Cambronero, J. (1995) Immunoprecipitation of a phospholipase D activity with antiphosphotyrosine antibodies. <i>J. Interferon Cytokine Res.</i> 15, 877-885								
			Abousalham, A., Riviere, M., Teissere, M., and Verger, R. (1993) Improved purification and biochemical characterization of phospholipase D from cabbage. <i>Biochim. Biophys. Acta</i> 1158, 1-7								
		Zhou, HL., Chabot-Fletcher, M., Foley, J. J., Sarau, H. M., Tzimas, M. N., Winkler, J. D., and Torphy, T. J. (1993) Association between leukotriene B ₄ -induced phospholipase D activation and degranulation of human neutrophils. <i>Biochem. Pharmacol.</i> 46, 139-148									
`		Shechter, I., Fogelman, A. M., and Popjak, G. (1980) A deficiency of mixed function oxidase activities in the cholesterol biosynthetic pathway of human granulocytes. <i>J. Lipid Res.</i> 21, 277-283									
•		Rabinowitz, J. L., Baker, D. G., Villanueva, T. G., Asanza, A. P., and Capuzzi, D. M. (1992) Liver lipid profiles of adults taking therapeutic doses of aspirin. <i>Lipids</i> 27, 311-314									
		Claria, J., and Serhan, C. N. (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. <i>Proc. Natl. Acad. Sci.</i> 92, 9475-9479									
		Serhan, C. N. (1997) Lipoxins and Novel Aspirin-Triggered 15-epi-Lipoxins: A Jungle of Cell-Cell Interactions or a Therapeutic Opportunity? <i>Prostaglandins</i> 53, 107-137									
		Exton, J.	H. (199	7) New developments ir	n phospholipase D. <i>J. Biol. Ch</i>	nem. 272, 15579-15582					
		factor and	d Rho p	hatmore, J., Morgan, C., proteins mediate fMLP-de <i>iol. Chem.</i> 273, 13157-13	, Jones, D., and Cockcroft, S. ependent activation of phosph 3164	(1998) ADP-ribosylation tolipase D in human					

Substitute	e for	form 1449A/	/PTO		Applica	ation Number	10/762,388		
INFO	\Q		N DI	SCI OSLIBE	Filing D	Date	January 22, 2004		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					First Na	amed Inventor	James L. Madara		
	- —	.IVI⊑IN I ny sheets a:			Art Unit	it _{ay} .	Unknown		
(use as ,	IIIGI	ly Silecio a.	3 110000	<u></u>	Examin	ner Name	Unknown		
Sheet	\prod	4	of	4	Attorne	ey Docket Number	7210.03		
OTHE	R D	OCUME	NTS -	NON-PATENT LITE	ERATUF	RE DOCUMENTS	3		
		Jarstfer, M. B., Blagg, B. S. J., Rogers, D. H., and Poulter, C. D. (1996) Biosynthesis of squalene. Evidence for a tertiary cyclopropylcarbinyl cationic intermediate in the rearrangement of presqualene diphosphate to squalene. <i>J. Amer. Chem. Soc.</i> 118, 13089-13090							
		Bach, T. 3 191-202	Bach, T. J. (1995) Some new aspects of isoprenoid biosynthesis in plantsa review. <i>Lipids</i> 30,						
		Serhan et al., "Aspirin-Triggered 15-EPI-Lipoxin A ₄ and Novel Lipoxin B ₄ Stable Analogs Inhibit Neutrophil-Mediated Changes in Vascular Permeability," <i>Advances in Experimental Medicine and Biology</i> , Vol. 469, 1999, pgs. 287-293							
		Gewirzt et al., "Pathogen-Induced Chemokine Secretion from Model Intestinal Epithelium is Inhibited by Lipoxin A ₄ Analogs", <i>Journal of Clinical Investigation</i> , Vol. 101, No. 9, May 1998, pgs. 1860-1869							
		Hansson et al., "Activation of Protein Kinase C By Lipoxin A and Other Eicosandoids. Intracellular Action of Oxygenation Products of Arachidonic Acid", <i>Biochemical and Biophysical Research Communications</i> , Vol. 134, No. 3, 1986, pgs. 1215-1222							
			Olson et al., "Biochemistry and cell biology of phospholipase D in human neutrophils", Chemistry and Physics of Lipids, 80, pp. 3-19, 1996						
		Takano et al., "Neutrophil-mediated Changes in Vascular Permeability Are Inhibited by Topical Application of Aspirin-triggered 15-epi-lipoxin A ₄ and Novel Lipoxin B ₄ Stable Analogues", J. Clin. Invest. Volume 101, Number 4, February 1998, pp. 819-826							
					•				
EXAMINER SIGNATURE DATE CONSIDERED									
*EXAMI	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through								

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

andrewski to

 $\frac{1}{\sqrt{1-\frac{2^2r^2}{r^2}}} = \frac{r^{2}}{r^2}$

al aparte Maria

									and Since, C.S. DELATTIMENT OF COMMENCE				
Substitute for form 1449A/PTO						Application Number		10/762,388					
INFORMATION DISCLOSURE						Filing	g C	Date	January 22, 2004				
STATEMENT BY APPLICANT						First Named Inventor		James L. Madara					
(use as many sheets as necessary)							ni	t Port Maria	Unknown				
	(40	e ao many	SHOOLO	as necessar	y)	Exam	nin	ner Name	Unknown				
Sheet		1	of	4		Attori	ne	ey Docket Number	7210.03				
					U.S. PA	rent	D	OCUMENTS					
*Examiner	Cite	DOC	UMENT N	IUMBER			Ī			Pages, Columns			
Initials	No.			de (if known)	Publication MM-DD-Y			Name of Patente Applicant of Cited Do				assages or ures Appear	
		US- 5,	441,951		8-1995		1	Serhan					
		US- 5,	648,512	2	7-1997	-	1	Serhan					
		US- 6,	353,026	}	3-2002		1	Serhan		. 1:			
		US- 6,	458,839)	10-2002		Ī	Madara et al.					
		US- 6,	699,905	5	3-2004	į	1	Madara et al.		····			
		US-						-					
				F	OREIGN F	PATEN	N٦	T DOCUMENTS					
						Printy No							
	:	FOREIGN PATENT DOCUMENT							Barra Or		TRANSLATION		
*Examiner	Cite No.	Country Code:		r - Kind Code i known)	Publication [I-DD-YYYY Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		THANSLA	TION		
		PCT	WO 9/	1/29262	12-1994			or Helevant	YES	NO			
		PCT		5/01179	1-1995								
		PCT		0/54767	9-2000								
		-				A \$50.00							
								The Page 1 of the Control of the Con	<u></u>				
				·				NT LITERATURE				POPUR. C. A	
*Examiner	Cite	In						, title of the article (when ap n, catalog, etc.), date, page			TRANSLA	TION	
Initials	No.			numb	er(s), publishe	r, city and	d/c	or country where published			YES	NO	
ē				Smolen, J. I neutrophils.				M. (1980) Release of ,27-34	f inflammato	ry mediators			
•			Serhan, C. N., Haeggstrom, J. Z., and Leslie, C. C. (1996) Lipid mediator networks in cell signaling: update and impact of cytokines. <i>FASEB J.</i> 10, 1147-1158										
		Weiss, S. J. (1989) Tissue destruction by neutrophils. N. Engl. J. Med. 320, 365-376											
				994) Lipoxin s. Acta 1212		is and	its	s impact in inflammat	ory and vas	cular events.			
				Naccache, 3, 459-468	P. H. (1990) Biosyı	/nti	thesis and biological	activity of le	ukotriene B ₄ .			

,	-										
Substitute for form 1449A/PTO					Application Number	10/762,388	·				
INFORMATION DISCLOSURE					Filing Date	January 22, 2004					
				APPLICANT	First Named Inventor	James L. Madara					
317				S as necessary)	Art Unit	Unknown					
	(นอ	e as many	SHEELS	as necessary)	Examiner Name	Unknown					
Sheet	Т	2	of	4	Attorney Docket Number	7210.03					
	OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS										
		Yokomizo	o, T., Iz	zumi, T., Chang, K., Tal	kuwa, T., and Shimizu, T. (1 chemotaxis. <i>Nature</i> 387, 620	1997) A G-protein-coupled					
		Fiore, S., A ₄ recept	Roma ors in h	no, M., Reardon, E. M., HL-60 cells. <i>Blood</i> 81, 33	and Serhan, C. N. (1993) Ind 395-3403	uction of functional lipoxin					
			y of a b		, Salvemini, D., Lee, L., an in Prostaglandin, Thromboxan						
		Chiang, N., Takano, T., Clish, C. B., Petasis, N. A., Tai, HH., and Serhan, C. N. (1998) Aspirintriggered 15-epi-lipoxin A ₄ (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA ₄ ELISA. <i>J. Pharmacol Exper. Ther.</i> 287, 779-790									
		Serhan, C. N., Maddox, J. F., Petasis, N. A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H. R., Colgan, S. P., and Madara, J. L. (1995) Design of lipoxin A ₄ stable analogs that block transmigration and adhesion of human neutrophils. <i>Biochemistry</i> 34, 14609-14615									
		Takano, T., Fiore, S., Maddox, J. F., Brady, H. R., Petasis, N. A., and Serhan, C. N. (1997) Aspirin-triggered 15-epi-lipoxin A ₄ (LXA ₄) and LXA ₄ Stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. <i>J. Exp. Med.</i> 185, 1693-1704									
		Owman, C., Garzino-Demo, A., Cocchi, F., Popovic, M., Sabirsh, A., and Gallo, R. (1998) The leukotriene B ₄ receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells. <i>Proc. Natl. Acad. Sci.</i> 95, 9530-9534									
		Marcus, A. J. (1995) Aspirin as prophylaxis against colorectal cancer. N. Engl. J. Med. 333, 656-658									
		Vainio, H., and Morgan, G. (1997) Aspirin for the second hundred years: new uses for an old drug. <i>Pharmacol Toxicol</i> 81, 151-152									
•		Herschman, H. R. (1998) Recent progress in the cellular and molecular biology of prostaglandin synthesis. <i>Trends in Cardiovasc. Med.</i> 8, 145-150									
,		Takano, T., Clish, C. B., Gronert, K., Petasis, N., and Serhan, C. N. (1998) Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epilipoxin A ₄ and novel lipoxin B ₄ stable analogues. <i>J. Clin. Invest.</i> 101, 819-826									
		Billah, M. M., Eckel, S., Mullmann, T. J., Egan, R. W., and Siegel, M. I. (1989) Phosphatidylcholine hydrolysis by phospholipase D determines phosphatidate and diglyceride levels in chemotactic peptide-stimulated human neutrophils. Involvement of phsophatidate phosphohydrolase in signal transduction. <i>J. Biol. Chem.</i> 264, 17069-17077									
		P. G., and	d Reyn	O., Martin, A., Hodgkin, nolds, J. L. (1997) Role a Vances in Enzyme Regul	M. N., Brown, F., Pettit, T. R. and regulation of phospholipas	., Cross, M. J., De Takats, se D activity in normal and					

and the second s

...

•	•			en e			•		
Substitute	for form 1449A	√PTO		Application Number	10/762,388				
MEC		^N	NOO! OOUDE	Filing Date	January 22, 2004				
			DISCLOSURE	First Named Inventor	James L. Madara				
			APPLICANT	Art Unit	Unknown				
(use as many	SHEELS	s as necessary)	Examiner Name	Unknown				
Sheet	3	of	4	Attorney Docket Number	7210.03				
	ТО	HER	DOCUMENTS - NOI	N-PATENT LITERATUR	E DOCUMENTS				
	Olson, S.	. C., and		Biochemistry and cell biology	····				
				and Lasala, D. J. (1998) Char plice variants. <i>FASEB J.</i> 12, 1					
	Wakelam	Martin, A., Saqib, K. M., Hodgkin, M. N., Brown, F. D., Pettit, T. R., Armstrong, S., and Wakelam, M. J. O. (1997) Role and regulation of phospholipase D signalling. <i>Biochem. Soc. Trans.</i> 25, 1157-1160							
		Levy, B. D., Petasis, N. A., and Serhan, C. N. (1997) Polyisoprenyl phosphates in intracellular signalling. <i>Nature</i> 389, 985-989							
	acid as a	Agwu, D. E., McPhail, L. C., Sozzani, S., Bass, D. A., and McCall, C. E. (1991) Phosphatidic acid as a second messenger in human polymorphonuclear leukocytes. Effects on activation of NADPH oxidase. <i>J. Clin. Invest.</i> 88, 531-539							
	Diacylgly	Pettit, T. R., Martin, A., Horton, T., Liossis, C., Lord, J. M., and Wakelam, M. J. O. (1997) Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively, have distinct fatty acid compositions and functions. <i>J. Biol. Chem.</i> 272, 17354-17359							
		Gomez-Cambronero, J. (1995) Immunoprecipitation of a phospholipase D activity with antiphosphotyrosine antibodies. <i>J. Interferon Cytokine Res.</i> 15, 877-885							
		Abousalham, A., Riviere, M., Teissere, M., and Verger, R. (1993) Improved purification and biochemical characterization of phospholipase D from cabbage. <i>Biochim. Biophys. Acta</i> 1158, 1-7							
	Torphy, 7	Zhou, HL., Chabot-Fletcher, M., Foley, J. J., Sarau, H. M., Tzimas, M. N., Winkler, J. D., and Torphy, T. J. (1993) Association between leukotriene B ₄ -induced phospholipase D activation and degranulation of human neutrophils. <i>Biochem. Pharmacol.</i> 46, 139-148							
		Shechter, I., Fogelman, A. M., and Popjak, G. (1980) A deficiency of mixed function oxidase activities in the cholesterol biosynthetic pathway of human granulocytes. <i>J. Lipid Res.</i> 21, 277-							
•				va, T. G., Asanza, A. P., and C doses of aspirin. <i>Lipids</i> 27, 31					
,		Claria, J., and Serhan, C. N. (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. <i>Proc. Natl. Acad. Sci.</i> 92, 9475-9479							
				l Aspirin-Triggered 15-epi-Lipo y? <i>Prostaglandins</i> 53, 107-137					
	Exton, J.	H. (199	37) New developments in	n phospholipase D. <i>J. Biol. Ch</i>	nem. 272, 15579-15582				
	factor and	d Rho p		Jones, D., and Cockcroft, S. ependent activation of phosph					

The second secon

Substitut	le for	form 1449A/	/PTO	·	Application Number	10/762,388				
l I INIEC	DI		NI DI	SCLOSURE	Filing Date	January 22, 2004				
				APPLICANT	First Named Inventor	James L. Madara				
		IVI⊑IN I ny sheets as			Art Unit	Unknown				
(นอะ สอ	· IIIai	ly sileels at	3 110000	ssary)	Examiner Name	Unknown				
Sheet	\Box	4	of	4	Attorney Docket Number	7210.03				
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS										
· .		Jarstfer, M. B., Blagg, B. S. J., Rogers, D. H., and Poulter, C. D. (1996) Biosynthesis of squalene. Evidence for a tertiary cyclopropylcarbinyl cationic intermediate in the rearrangement of presqualene diphosphate to squalene. <i>J. Amer. Chem. Soc.</i> 118, 13089-13090								
		Bach, T. J 191-202	J. (1995	S) Some new aspects of	isoprenoid biosynthesis in pla	antsa review. <i>Lipids</i> 30,				
		Serhan et al., "Aspirin-Triggered 15-EPI-Lipoxin A ₄ and Novel Lipoxin B ₄ Stable Analogs Inhibit Neutrophil-Mediated Changes in Vascular Permeability," <i>Advances in Experimental Medicine and Biology</i> , Vol. 469, 1999, pgs. 287-293								
		Gewirzt et al., "Pathogen-Induced Chemokine Secretion from Model Intestinal Epithelium is Inhibited by Lipoxin A ₄ Analogs", <i>Journal of Clinical Investigation</i> , Vol. 101, No. 9, May 1998, pgs. 1860-1869								
		Hansson et al., "Activation of Protein Kinase C By Lipoxin A and Other Eicosandoids. Intracellular Action of Oxygenation Products of Arachidonic Acid", <i>Biochemical and Biophysical Research Communications</i> , Vol. 134, No. 3, 1986, pgs. 1215-1222								
		Olson et al., "Biochemistry and cell biology of phospholipase D in human neutrophils", Chemistry and Physics of Lipids, 80, pp. 3-19, 1996								
		Takano et al., "Neutrophil-mediated Changes in Vascular Permeability Are Inhibited by Topical Application of Aspirin-triggered 15-epi-lipoxin A₄ and Novel Lipoxin B₄ Stable Analogues", J. Clin. Invest. Volume 101, Number 4, February 1998, pp. 819-826								
		et en et								
EXAMIN	EXAMINER SIGNATURE				DATE CONSIDERED					
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									